Insmed Reports Q3 Revenue of $524.4 Million, Raises 2026 Guidance
Third-quarter 2026 revenue rose 268% year over year to $524.4 million; Insmed reported a net loss of $100.3 million, or $0.46 per share, and raised full-year revenue guidance for BRINSUPRI and ARIKAYCE.
Story updates
11:09:14 AM UTC
SquawkNews
Insmed Raises 2026 BRINSUPRI Rev Guidance to $1.35B-$1.4B >INSM
11:09:39 AM UTC
SquawkNews
Insmed Raises 2026 ARIKAYCE Rev Guidance to $460M-$470M >INSM
11:11:38 AM UTC
SquawkNews
Insmed reported third-quarter 2026 revenue of $524.4M, up 268% from $142.3M a year earlier, driven mainly by BRINSUPRI sales growth. The company posted a net loss of $100.3M, or $0.46 per diluted share, compared with a net loss of $370M, or $1.75 per diluted share, in the prior-year quarter.Financi…
11:14:36 AM UTC
SquawkNews
*--Earnings Flash (INSM) Insmed Posts Q3 Loss $0.46 a Share, vs. FactSet Est of $0.38 Loss
11:18:23 AM UTC
SquawkNews
Insmed: Nettoverlust im dritten Quartal 2026 sinkt gegenüber Vorjahr um 73 Prozent auf 100.3 Million
11:19:42 AM UTC
SquawkNews
Insmed, perdita netta del terzo trimestre 2026 in calo del 73% annuo a 100,32 milioni di dollari; ri
Insmed reported third-quarter 2026 revenue of $524.4 million, up 268% from a year earlier, and a net loss of $100.3 million, or $0.46 per share. The company raised its full-year revenue guidance for both BRINSUPRI and ARIKAYCE. It also reported progress across its respiratory pipeline and launched…